Abstract:Objective: Post-stroke epilepsy (PSE) is associated with increased morbidity and mortality. Stroke-associated acute symptomatic seizures are an important risk factor: 20.8–34.3% of these patients will go on to develop PSE. Identifying these “high risk” individuals may result in earlier PSE diagnosis, treatment, and avoidance of seizure-related morbidity. This study was to identify predictors of PSE development in patients with stroke-associated acute symptomatic seizures. Participants and Methods: This was a retrospective cohort study of 167 patients with stroke-associated acute symptomatic seizures admitted to the Neurology Department of a tertiary Hospital of China, from 1 May 2006 to 30 January 2020. Both those with primary ischemic stroke and intracerebral hemorrhage were included in the study. Patient demographics, medical history, stroke-associated, and seizure-related variables were evaluated with univariable analysis and multivariable Cox regression analysis. PSE was defined as unprovoked seizures occurring > 7 days post-stroke. Data points were extracted from medical records and supplemented by tele-interview. Results: Of the 167 patients with stroke-associated acute symptomatic seizures, 49 (29.3%) developed PSE. NIHSS score > 14 [hazard ratio (HR) 2.98, 95% CI 1.57–5.67], longer interval from stroke to acute symptomatic seizures (days 4–7 post-stroke) (HR 2.51, 95% CI 1.37–4.59) and multiple acute symptomatic seizures (HR 5.08, 95% CI 2.58–9.99) were independently associated with PSE development. This association remained in the sub-analysis within the ischemic stroke cohort. In the sub-analysis of the hemorrhagic stroke cohort, multilobar involvement (HR 4.80, 95% CI 1.49–15.39) was also independently associated with development of PSE. Further, we developed a nomogram to predict individual risk of developing PSE following stroke-associated acute symptomatic seizures. The nomogram showed a C-index of 0.73. Conclusion: More severe neurofunctional deficits (NIHSS score > 14), longer interval from stroke to acute symptomatic seizures (days 4–7 post-stroke), and multiple acute symptomatic seizures were independently associated with development of PSE in patients with stroke-associated acute symptomatic seizures. This knowledge may increase clinical vigilance for development of PSE, facilitating rapid diagnosis and treatment initiation, and subsequently reduce seizure-related morbidity.

Advances in clinical research on post-stroke seizure

Research Advances in Post-stroke Seizure and Post-stroke Epilepsy

The Progress of Poststroke Seizures

Clinical approaches for poststroke seizure: a review

Pathophysiology, Diagnosis, Prognosis, and Prevention of Poststroke Epilepsy: Clinical and Research Implications

Image post-processing in magnetic resonance imaging-negative focal epilepsy

Research Progress of Natural Products for the Treatment of Ischemic Stroke.

Research progress of natural products for the treatment of ischemic stroke

Poststroke Seizure and Epilepsy: A Review of Incidence, Risk Factors, Diagnosis, Pathophysiology, and Pharmacological Therapies

Incidence, Implications, and Management of Seizures Following Ischemic and Hemorrhagic Stroke

[Risk factors for post stroke epilepsy]

Stroke-related epilepsy

Applications of Electroencephalography in the Management of Stroke Patients

Association Between Different Acute Stroke Therapies and Development of Post Stroke Seizures

Electroencephalogram findings in 10 patients with post-stroke epilepsy: A retrospective study

Treating Post-stroke Epilepsy in a Patient With Multiple Comorbidities

Recent advances in the development of neuroprotective agents and therapeutic targets in the treatment of cerebral ischemia

Post-stroke epilepsy

Risk of Post-stroke Epilepsy Following Stroke-Associated Acute Symptomatic Seizures

The sensation of dyspnea during exercise is not determined by the work of breathing in patients with heart failure.

Post-Stroke Neuropsychiatric Complications: Types, Pathogenesis, and Therapeutic Intervention